Rim Diab: Presenting Protein S Research as a Rebalancing Strategy at ISTH 2026
Rim Diab, Scientist-Postdoc Researcher, Research Assistant, shared a post on LinkedIn:
“Grateful for the opportunity to share our latest research at the International Society on Thrombosis and Haemostasis (ISTH) 2026.
I had the privilege of presenting our work on Protein S as a hemostatic rebalancing strategy in both Factor XI deficiency and von Willebrand disease. It was a valuable experience to discuss these projects with researchers and clinicians from around the world.
A heartfelt thank you to my supervisors, Anne Angelillo-Scherrer and Raja Prince, for their guidance, support, and encouragement throughout these projects. I am also grateful to all my colleagues and collaborators whose contributions made this work possible.
I feel very fortunate to be part of BLEEDnFIRE Therapeutics to contribute to the development of new therapeutic approaches for bleeding disorders.”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 11:21Thrombotic Microangiopathies: From Clinical Syndrome to Molecularly Targeted Therapy
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease